Table 3 Comparison of treatment of NSCLC between the IPF and no-IPF groups.

From: Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients

Characteristics

IPF

No-IPF

P-value

Number of patients

104

416

 

Resectable case

66 (63.5)

267 (64.2)

0.891

Surgery

55 (52.9)

197 (47.4)

0.313

Types of surgery

  

< 0.001

Lobar resectiona

32 (58.2)

175 (88.8)

 

Sublobar resectionb

23 (41.8)

22 (11.2)

 

Chemotherapy

33 (31.7)

134 (32.2)

0.925

Target therapyc (n = 39/156)

4 (10.1)

32 (20.5)

0.140

Target therapy regimen

  

0.319

Gefitinib

3 (75.0)

19 (59.4)

 

Erlotinib

0

9 (28.1)

 

Gefitinib + Erlotinib

0

2 (6.3)

 

Afatinib

1 (25.0)

1 (3.1)

 

Crizotinib

0

1 (3.1)

 

Radiation therapy

23 (22.1)

65 (15.6)

0.114

Types of RT

  

0.015

SRS or SBRT

12 (52.2)

16 (24.6)

 

Conventional RT

11 (47.8)

49 (75.4)

 
  1. Data are presented as number (%), unless otherwise indicated.
  2. NSCLC non-small cell lung cancer, IPF idiopathic pulmonary fibrosis, RT radiation therapy, SRS stereotactic radiosurgery, SBRT stereotactic body radiotherapy.
  3. aLobar resection: lobectomy or more extensive resection (bilobectomy or pneumonectomy).
  4. bSublobar resection: segmentectomy or wedge resection.
  5. cInformation from only adenocarcinoma patients.
Back to article page